Alto Neuroscience (NYSE:ANRO) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Alto Neuroscience (NYSE:ANRO) from a hold rating to a sell rating in a research note published on Saturday morning.

A number of other analysts also recently issued reports on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $35.00 price objective on shares of Alto Neuroscience in a report on Monday, March 16th. BTIG Research raised their target price on shares of Alto Neuroscience from $27.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Robert W. Baird raised their target price on Alto Neuroscience from $22.00 to $41.00 and gave the stock an “outperform” rating in a research note on Wednesday, March 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Alto Neuroscience in a research report on Monday, December 29th. Finally, Chardan Capital reiterated a “buy” rating and issued a $30.00 price target on shares of Alto Neuroscience in a research note on Tuesday, March 17th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $34.33.

Alto Neuroscience Trading Down 7.2%

NYSE:ANRO opened at $19.92 on Friday. The company has a current ratio of 15.69, a quick ratio of 15.69 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $636.49 million, a PE ratio of -9.14 and a beta of 2.52. Alto Neuroscience has a 12 month low of $1.60 and a 12 month high of $25.17. The firm’s 50 day moving average is $18.53 and its 200 day moving average is $13.85.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Monday, March 16th. The company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.11. Sell-side analysts expect that Alto Neuroscience will post -2.54 earnings per share for the current year.

Institutional Trading of Alto Neuroscience

Hedge funds have recently made changes to their positions in the business. Vestal Point Capital LP raised its stake in shares of Alto Neuroscience by 161.6% in the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock valued at $44,233,000 after acquiring an additional 1,535,000 shares during the period. Commodore Capital LP bought a new position in shares of Alto Neuroscience during the 4th quarter worth $32,453,000. Perceptive Advisors LLC increased its position in Alto Neuroscience by 1,048.5% during the 4th quarter. Perceptive Advisors LLC now owns 1,784,393 shares of the company’s stock valued at $31,762,000 after purchasing an additional 1,629,027 shares during the period. Armistice Capital LLC raised its stake in Alto Neuroscience by 0.7% in the third quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock worth $6,577,000 after buying an additional 12,000 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Alto Neuroscience by 1.9% in the 3rd quarter. Vanguard Group Inc. now owns 1,105,407 shares of the company’s stock worth $4,444,000 after acquiring an additional 20,702 shares in the last quarter.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.